GLG News by General Cardiologists (US)

This is great news for Canada.  This is the first new drug approved for the treatment of acute heart failure since 1989, when milrinone was approved.  Nesiritide was approved in the United States in 2001.  Since then, it has proven to be of great benefit in patients with acute heart failure,...

This is no real solution to the medicare problem. EMR and the medicare cuts are really separate issues. These type of mandates will make it almost impossible for small practices.

The CorE 64 is the latest in coronary imaging technologies, but it is unclear what the provided results mean and what doctors need to do about them. The results of the initial study presented at the American Heart Association Scientific Sessions sparked an intense debate about the role of coronary computed...

As past Principal Investigator in most clinical trials wit Orlistat I can offer a different interpretations of tthe resuls of the comparayive study just announced,as follows.1.The result on diabetes or glucose regulation were earlier with Liraglutide,possibly because it has specific antidiabetic(besides...

The meta-analysis of the rimonabant trials points to an increase in psychiatric diagnoses. What is missing in this report is the numberical and statistical significance of the findings.  This debate needs more rigor; the type of rigor that is applied to cardiac endpoints, needs to be applied here. ...

No safety signal so far giving problems is obviously a good sign.  Thsi magnitude of weight loss beats all other pharmacologic weight loss options so far.

Most diabetics have subclinical CAD, and a baseline risk of CAD equivalent to that of a person without diabetes and a prior MI.  This drug, by limiting its labelling is severely limiting its use in patients with diabetes.

These results are encouraging for ranexa.  Ranexa has been a niche drug until now.  There are so many therapies for angina, that it is rare for a patient to be refractory to standard therapy.  I am a practicing cardiologist and I can only recall using this drug on one patient to date. ...

Current standard is plavix, aspirin, and IIbIIIa inhibitor or/and bivalrudin/lovenox/heparin in the setting of acute coronary syndrome(threatened MI) requiring intervention.  It is no surprise that Integrillin  plus plavix works better than plavix alone to inhibit platelets, since they inhibit...

By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...